RxDoctor Payments Data

Angelo Constantino, MD

Internal Medicine · Pittsburgh, PANPI 1669479283

Payments from drug & device makers

$16,108in general payments, 2019–2025

Across 789 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Novo Nordisk$2K
  • Amgen$2K
  • AbbVie$2K
  • GSK$1K
  • AstraZeneca$1K
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$16,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,108 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$119,046
Medicare patients
118
Services billed
4,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$114,092
EliquisApixaban119$104,089
Enbrel SureclickEtanercept14$103,057
XareltoRivaroxaban55$64,386
Synjardy XrEmpagliflozin/Metformin Hcl44$40,888
MyrbetriqMirabegron87$36,637
ProliaDenosumab18$31,570
JardianceEmpagliflozin24$30,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$27,478
OxycontinOxycodone Hcl18$25,469
EntrestoSacubitril/Valsartan13$18,596
LinzessLinaclotide24$17,865
MounjaroTirzepatide17$17,095
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$13,566
JanuviaSitagliptin Phosphate15$10,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,714$114,092111 claims
PfizerEliquis$212$104,089119 claims
Boehringer IngelheimSynjardy Xr, Jardiance$889$71,31868 claims
Johnson & JohnsonXarelto$2,151$64,38655 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,205$41,04461 claims
Astellas Pharma US IncMyrbetriq$347$36,63787 claims
AmgenProlia$1,713$31,57018 claims
AbbVieLinzess, Synthroid$1,644$20,56060 claims
NovartisEntresto$195$18,59613 claims
Lilly USA, LLCMounjaro$775$17,09517 claims
MerckJanuvia$577$10,26615 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$320$9,42011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →